Sign In
Buy VANI
$1.42
+0.0600 (+4.41%)
At Close: Jul 13, 2026
ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting
ClearOne Announces Entry into Merger Agreement with Cortigent, Inc., a Wholly-Owned Subsidiary of Vivani Medical
08:00am, Thursday, 02'nd Jul 2026
SALT LAKE CITY--(BUSINESS WIRE)--ClearOne, Inc. (Nasdaq: CLRO) (“ClearOne”) announced today that it has entered into a definitive agreement and plan of merger (the “Agreement”) among its wholl
Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.
08:00am, Thursday, 02'nd Jul 2026
Vivani proposes to merge Cortigent, Inc. with a wholly owned subsidiary of ClearOne, Inc. (Nasdaq: CLRO), and change the listed company's name and ticker to Cortigent Holdings, Inc. (d/b/a Cortigent)
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
07:30am, Friday, 26'th Jun 2026
ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-
ALAMEDA, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention
04:03pm, Monday, 22'nd Jun 2026
ALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI ) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra lon
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
04:05pm, Wednesday, 13'th May 2026
Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic weight management, on track for mid-year 2026 $28 million in cash, cash equivale
Insider Buying: Vivani Medical (NASDAQ:VANI) Director Purchases $1,999,999.26 in Stock
04:22am, Sunday, 19'th Apr 2026
Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) Director Gregg Williams purchased 1,587,301 shares of the firm's stock in a transaction that occurred on Wednesday, April 15th. The stock was purc
Vivani Medical, Inc. (NASDAQ:VANI) Short Interest Up 65.0% in March
02:20am, Wednesday, 15'th Apr 2026
Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) was the recipient of a significant increase in short interest in the month of March. As of March 31st, there was short interest totaling 532,131 s
Critical Survey: Verrica Pharmaceuticals (NASDAQ:VRCA) vs. Vivani Medical (NASDAQ:VANI)
01:03am, Sunday, 05'th Apr 2026
Vivani Medical (NASDAQ: VANI - Get Free Report) and Verrica Pharmaceuticals (NASDAQ: VRCA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast th
Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Friday, 03'rd Apr 2026
Vivani Medical (VANI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
04:16pm, Thursday, 26'th Mar 2026
Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant advance NPM-139, miniature, ultra long-acting semaglutide implant under
Vivani Medical (VANI) Projected to Post Quarterly Earnings on Monday
02:32am, Monday, 23'rd Mar 2026
Vivani Medical (NASDAQ: VANI - Get Free Report) is projected to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Vivani Medical to post earnings of ($0.10) per s
Short Interest in Vivani Medical, Inc. (NASDAQ:VANI) Decreases By 25.4%
01:55am, Monday, 16'th Mar 2026
Vivani Medical, Inc. (NASDAQ: VANI - Get Free Report) was the recipient of a significant decrease in short interest in February. As of February 27th, there was short interest totaling 290,597 shares,
Contrasting Vivani Medical (NASDAQ:VANI) & VYNE Therapeutics (NASDAQ:VYNE)
01:58am, Sunday, 15'th Mar 2026
VYNE Therapeutics (NASDAQ: VYNE - Get Free Report) and Vivani Medical (NASDAQ: VANI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two comp
